New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
08:07 EDTCLDX, BMYCelldex to collaborate with Bristol-Myers on varlilumab/nivolumab combo therapy
Bristol-Myers Squibb (BMY) and Celldex Therapeutics (CLDX) announced that they have entered into a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of nivolumab, Bristol-Myers' investigational PD-1 immune checkpoint inhibitor, and varlilumab, Celldex’s CD27 targeting investigational antibody in a Phase 1/2 study. Multiple tumor types will be explored in the study, which could potentially include non-small cell lung cancer, metastatic melanoma, ovarian, colorectal and squamous cell head and neck cancers. Under the terms of this agreement, Bristol-Myers Squibb will make a one-time payment of $5M to Celldex and the parties will share development costs. Celldex will be responsible for conducting the Ph 1/2 study, which is expected to begin in the fourth quarter of 2014. Additionally, the parties have re-structured an existing agreement between Celldex and Medarex related to Celldex’s CD27 program, and waived certain future milestone payments and reduced future royalty rates that would have been due from Celldex to Medarex. Medarex was acquired by Bristol-Myers Squibb in September of 2009. The companies will work exclusively with each other to explore anti-PD-1 antagonist antibody and anti-CD27 agonist antibody combination regimens. Bristol-Myers Squibb will have a time-limited right of first negotiation if Celldex wishes to out-license varlilumab.
News For CLDX;BMY From The Last 14 Days
Check below for free stories on CLDX;BMY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
07:43 EDTBMYBofA/Merrill to hold a conference
Subscribe for More Information
September 16, 2014
06:00 EDTBMYBristol-Myers announces Health Canada approval of Yervoy
Subscribe for More Information
September 5, 2014
16:45 EDTBMYMarket ends week little changed after mixed economic data
Subscribe for More Information
11:17 EDTBMYBristol-Myers files patent infringement suit against Merck
Subscribe for More Information
September 4, 2014
08:02 EDTBMYTeva launches generic Baraclude in U.S.
Teva (TEVA) announces the launch of the generic equivalent to Baraclude tablets in the U.S. Teva was first to file, making the product eligible for 180 days of marketing exclusivity. Baraclude is marketed by Bristol-Myers Squibb (BMY).

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use